🇺🇸 EconoPred Plus in United States

41 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 41

Most-reported reactions

1. Anterior Chamber Inflammation — 9 reports (21.95%)
2. Visual Acuity Reduced — 6 reports (14.63%)
3. Nausea — 5 reports (12.2%)
4. Macular Oedema — 4 reports (9.76%)
5. Drug Ineffective — 3 reports (7.32%)
6. Endophthalmitis — 3 reports (7.32%)
7. Headache — 3 reports (7.32%)
8. Postoperative Infection — 3 reports (7.32%)
9. Visual Disturbance — 3 reports (7.32%)
10. Alopecia — 2 reports (4.88%)

Source database →

Frequently asked questions

Is EconoPred Plus approved in United States?

EconoPred Plus does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for EconoPred Plus in United States?

Indiana University School of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.